Analyses carried out on ccRCC cells treated with shRNAs against NNMT mRNA showed that the enzyme can promote cellular invasiveness both in vitro and in vivo, with the activation of the PI3K/Akt/SP1/MMP-2 pathway [31]. The gene discussed is NNMT; the disease is nonpapillary renal cell carcinoma.